April 3, 2018

Verseon Corporation (“Verseon” or the “Company”)

Additional Listing and Total Voting Rights

Fremont, Calif.—Verseon, a technology-based pharmaceutical company, announces that application has been made for 24,650 new shares of common stock (“Common Shares”) of par value $0.001 each to be admitted to trading on AIM pursuant to regularly scheduled vesting of restricted stock units and warrant exercise (the "Issuance"). The restricted stock units (“RSU”) have been issued to Dr. Thomas Hecht and Dr. Robert Karr, both non-executive Directors of the Company, in relation to the payment of their Director’s fees as previously disclosed. Of the 24,650 Common Shares issued, 9,036 Common Shares were issued to Dr. Hecht and 9,036 to Dr. Karr.

Following the Issuance, Dr. Hecht will hold 72,436 Common Shares, representing 0.05% of the Company’s issued share capital. Dr. Karr will hold 200,324 Common Shares, representing 0.13% of the Company’s issued share capital.

The 24,650 new Common Shares issued pursuant to the Issuance will rank pari passu with the Company's existing Common Shares and admission to trading on AIM is expected to take place on April 9, 2018 ("Admission").

Total Voting Rights

Following Admission, the issued share capital of the Company will consist of 151,595,595 Common Shares and the Company will hold 42,917 shares in treasury. Therefore, the total number of Common Shares in the Company with voting rights will be 151,552,678. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

-Ends-

For further information please contact:

Verseon Corporation
Sebastian Wykeham / Tina Schlafly +1 (510) 225 9000
   
Cenkos (NOMAD and Joint Broker)  
Neil McDonald / Beth McKiernan +44 (0) 20 7397 8900
   
Cantor Fitzgerald Europe (Joint Broker)  
Marc Milmo / Phil Davies / Callum Butterfield +44 (0) 20 7894 7000
   

For financial and business media enquiries, please contact

Buchanan Communications Ltd (PR Advisors)
Henry Harrison-Topham / Jamie Hooper +44 (0) 20 7466 5000
   

For trade and pharma media enquiries, please contact

Vane Percy & Roberts
Simon Vane Percy +44 (0) 1737 821 890

Our pledge

Verseon is committed to growth through innovation, building value for its shareholders while respecting its responsibilities as a good corporate citizen